A Long-Term Study of Bivamelagon in Participants With Hypothalamic Obesity (HO)

Enrolling by invitation · Phase 2

Conditions studied: Hypothalamic Obesity

In brief

This is a long-term, open-label extension study of bivamelagon in participants with Hypothalamic Obesity (HO) who have transitioned from the index study, LG-MCCL005. The study will last up to 2 years.

Key facts

Study ID

NCT07156578

Run by

Rhythm Pharmaceuticals, Inc.

People needed

25

Starts

2025-11-10

Expected to finish

2028-04-15

Last updated by the study team

2026-02-10

Who can join

Age: 12 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Children's Hospital Colorado — Aurora, Colorado, United States
• University of Iowa Children's Hospital — Iowa City, Iowa, United States
• Tufts Medical Center — Boston, Massachusetts, United States
• Columbia University — New York, New York, United States
• The University of North Carolina at Chapel Hill — Chapel Hill, North Carolina, United States
• St. Jude Children's Research Hospital — Memphis, Tennessee, United States
• Birmingham Women's and Children's NHS Foundation Trust — Birmingham, United Kingdom
• University of Cambridge — Cambridge, United Kingdom
• Great Ormond Street Hospital for Children — London, United Kingdom

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.